Compound probiotics capable of improving immunity and functional yoghourt prepared from compound probiotics
By using the complex probiotic fermented milk composed of Lactobacillus Swiss, Lactobacillus reuteri and Bifidobacter brevitro to prepare functional yogurt, the problem of insufficient immunity in modern society was solved, and the effect of significantly improving immunity was achieved. Ensures the safety of the product.
Patent Information
- Application Number
- CN202411299030.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-18
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-09-18
AI Technical Summary
In modern society, people are not immune enough, and it is difficult to effectively enhance them through routine exercise, and there is a lack of safe and efficient method to improve immunity.
Functional yogurt was prepared to enhance immunity by using a complex probiotic composed of Lactobacillus Swiss LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacter brevis FPHC4024.
It significantly improves the spleen index, thymus index and humoral immunity, enhances immunity, and has high safety and is not easy to develop resistance.
Smart Images

Figure CN118909883A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of probiotics, and in particular to a composite probiotic for improving immunity and a functional yogurt prepared therefrom. Background Art
[0002] Probiotics have a close relationship with humans. They are the most important beneficial bacteria in the human intestines and play an important role in human nutrition, immunity, health care, and even anti-aging and longevity. The higher the proportion of probiotics in the human intestine, the better the microecological environment, and the younger and more energetic the intestines appear.
[0003] The probiotics that have been discovered and used so far mainly include the following three categories: Lactobacillus, such as lactic acid bacteria, Lactobacillus rhamnosus, Lactobacillus acidophilus, etc.; Bifidobacterium, such as Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium bifidum, etc.; other bacterial genera, such as Streptococcus thermophilus, Pediococcus acidilactici, yeast, etc.
[0004] Chinese patent CN116970530A discloses a Bifidobacterium breve FPHC4024, which can cause the absorption of excess water in the colon and has a good effect in preventing, alleviating and treating diarrhea in children. Chinese patent CN117018043A discloses a probiotic strain and its application, a composition for preventing and treating diarrhea in children, wherein the probiotic strain is Lactobacillus reuteri FPH2951.
[0005] Immunity is an active defense mechanism of the human body, which is of great significance to maintaining physiological and life activities. The immune cells that maintain the immune function of the human body include T cells, B cells, neutrophils, and macrophages. Insufficient or excessive immunity will bring adverse effects to oneself, mainly manifested as loss of appetite, malnutrition, mental confusion, physical weakness, fatigue, sleep disorders, etc. In modern society, with the improvement of health awareness, people also have higher requirements for the prevention and treatment of "pre-disease". However, due to the fast pace of modern society, most people cannot exercise every day to enhance their immunity. Therefore, it is particularly important for human health to seek safer and more effective ways to enhance immunity. Summary of the invention
[0006] In view of the above-mentioned prior art, the present invention provides a composite probiotic for improving immunity and a functional yogurt prepared therefrom.
[0007] To achieve the above object, the present invention adopts the following technical solution: One aspect of the present invention provides a composite probiotic for improving immunity, wherein the composite probiotic consists of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024.
[0008] Furthermore, the Lactobacillus helveticus LZ-R-5 was deposited in the General Microbiology Center of China Microorganism Culture Collection Administration on June 24, 2021, with the deposit address being No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, and the deposit number being CGMCC NO.22776; The Lactobacillus reuteri FPHC2951 was deposited in the Guangdong Provincial Microbiological Culture Collection Center on November 3, 2022, with the deposit address being 5th Floor, Building 59, No. 100, Xianlie Middle Road, Guangzhou City, Guangdong Province, China, and the deposit number is GDMCCNO.62946; The Bifidobacterium breve FPHC4024 was deposited in the Guangdong Provincial Microbiological Culture Collection Center on November 3, 2022, with the storage address being 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou City, Guangdong Province, China, and the storage number is GDMCCNO.62945.
[0009] Furthermore, the ratio of the live counts of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 is 1-3:1-3:3-6.
[0010] Furthermore, the ratio of the live bacteria counts of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 is 2:2:3-6.
[0011] Furthermore, the ratio of the live bacteria counts of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 is 2:2:5.
[0012] Furthermore, in the composite probiotics, the total viable count of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 is 5-9×10 9 cfu / mL.
[0013] The preparation method of the composite probiotics of the present invention is as follows: Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951, and Bifidobacterium breve FPHC4024 are thawed and activated respectively, and then statically cultured in an MRS medium at 37°C for 24 hours according to an inoculation amount of 2%, and the obtained bacterial culture is centrifuged at 6000rpm for 10 minutes to obtain three single bacterial bodies respectively; the three bacterial bodies are freeze-dried to obtain freeze-dried bacterial powders, wherein the ratio of the live bacterial counts of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951, and Bifidobacterium breve FPHC4024 is 1-3:1-3:3-6, and the total live bacterial counts of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951, and Bifidobacterium breve FPHC4024 are 8×10 9 The composite probiotics were prepared at a rate of 1.0 cfu / mL.
[0014] In a second aspect, the present invention also provides the use of the composite probiotics in the preparation of health products for improving immunity.
[0015] In a third aspect, the present invention further provides a functional yogurt, wherein the functional yogurt is obtained by inoculating the above-mentioned composite probiotics into fresh milk with sugar, and then fermenting and ripening the milk.
[0016] Furthermore, the ratio of the live counts of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 is 1-3:1-3:3-6; the total live counts of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 are 5-9×10 9 cfu / mL; fermentation temperature is 33-38℃, fermentation time is 12-18h; ripening temperature is 4-8℃, ripening time is 30-40h.
[0017] Furthermore, the ratio of the live counts of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 is 1-3:1-3:3-6; the total live counts of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 are 6-8×10 9 cfu / mL; fermentation temperature was 35℃, fermentation time was 15h; ripening temperature was 6℃, ripening time was 35h.
[0018] Furthermore, the ratio of the live counts of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 is 2:2:5; the total live counts of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 are 8×10 9 cfu / mL; fermentation temperature was 35℃, fermentation time was 15h; ripening temperature was 6℃, ripening time was 35h.
[0019] Furthermore, the sugar is white sugar, and the ratio of the white sugar to fresh milk is 6-10g:100mL.
[0020] Furthermore, the ratio of white sugar to fresh milk is 8.6g:100mL.
[0021] The composite probiotics of the invention are composed of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024, and produce a synergistic effect in the process of fermenting milk. The ratio of the live bacteria counts of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 is 1-3:1-3:3-6, and the functional yogurt prepared has a significant immune enhancement effect.
[0022] In a fourth aspect, the present invention further provides a functional yogurt powder, which is prepared by spray-drying the above functional yogurt.
[0023] Compared with the prior art, the present invention has the following beneficial effects: The composite probiotics for improving immunity of the present invention significantly increase body weight, improve spleen index and thymus index, improve phagocytosis rate and phagocytosis index, and significantly improve immunity. The functional yogurt obtained by fermentation of the composite probiotics of the present invention significantly improves spleen index and thymus index, increases IgG, IgA and IgM content in serum, and enhances humoral immunity.
[0024] After a lot of analysis and experiments, the present invention combines three strains of different performances, Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024, in a certain proportion, and produces a synergistic effect between the three strains, which has a significant technical advantage in improving immunity. Compared with a single strain, the composite probiotic of the present invention has a better effect of improving immunity. The three strains of the present invention are all probiotics, the product has high safety, is not easy to produce resistance, and has good safety and application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] In order to more clearly illustrate the technical solutions in the present invention or the prior art, the drawings required for the specific implementation methods are briefly introduced below.
[0026] Figure 1 The figure is a schematic diagram of the effect of the composite probiotics of the present invention on body weight; compared with the blank control group, # p<0.05, ## p<0.01; compared with the Example 1 group, **p<0.01.
[0027] Figure 2 The figure is a schematic diagram showing the effect of the composite probiotics of the present invention on the spleen index; compared with the blank control group, # p<0.05, ## p<0.01; compared with the Example 1 group, **p<0.01.
[0028] Figure 3 The figure is a schematic diagram showing the effect of the composite probiotics of the present invention on the thymus index; compared with the blank control group,# p<0.05, ## p<0.01; compared with the Example 1 group, **p<0.01.
[0029] Figure 4 The figure is a schematic diagram showing the effect of the composite probiotics of the present invention on the phagocytic rate; compared with the blank control group, # p<0.05, ## p<0.01; compared with the Example 1 group, **p<0.01.
[0030] Figure 5 The figure is a schematic diagram showing the effect of the composite probiotics of the present invention on the phagocytic index; compared with the blank control group, # p<0.05, ## p<0.01; compared with the Example 1 group, **p<0.01.
[0031] Figure 6 The figure is a schematic diagram showing the effect of the functional yogurt of the present invention on the IgG content; compared with the blank control group, # p<0.05, ## p<0.01; compared with the group in Example 5, **p<0.01.
[0032] Figure 7 The figure is a schematic diagram showing the effect of the functional yogurt of the present invention on the IgA content; compared with the blank control group, # p<0.05, ## p<0.01; compared with the group in Example 5, **p<0.01.
[0033] Figure 8 Schematic diagram of the effect of the functional yogurt of the present invention on the IgM content; compared with the blank control group, # p<0.05, ## p<0.01; compared with the group in Example 5, *p<0.05. DETAILED DESCRIPTION
[0034] The technical solution of the present invention will be described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0035] The experimental methods described in the following examples are conventional methods unless otherwise specified; the reagents and materials described are commercially available unless otherwise specified.
[0036] The strains used in the following examples of the present invention are derived from the following: Lactobacillus helveticus LZ-R-5 was deposited at the General Microbiology Center of China Microbiological Culture Collection Administration on June 24, 2021. The deposit address is No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, and the deposit number is CGMCC NO.22776. Lactobacillus reuteri FPHC2951 was deposited in Guangdong Microbiological Culture Collection Center on November 3, 2022, with the deposit address at 5th Floor, Building 59, No. 100, Xianlie Middle Road, Guangzhou, Guangdong, China, and the deposit number is GDMCC NO. 62946. Lactobacillus reuteri FPHC2951 has been disclosed in patent CN117018043A.
[0037] Bifidobacterium breve FPHC4024 was deposited in Guangdong Microbiological Culture Collection Center on November 3, 2022, with the deposit address being 5th Floor, Building 59, No. 100, Xianlie Middle Road, Guangzhou, Guangdong, China, with the deposit number being GDMCC NO. 62945. Bifidobacterium breve FPHC4024 has been disclosed in patent CN116970530A.
[0038] Lactobacillus reuteri LR06 was deposited at the General Microbiology Center of China National Microbiological Culture Collection Administration on June 24, 2021. The deposit address is No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing. The deposit number is CGMCC NO. 22775. Lactobacillus reuteri LR06 has been disclosed in patent CN114468305A.
[0039] The components of MRS medium (g / L) are as follows: peptone 10 g / L, beef extract 10 g / L, glucose 15 g / L, lactose 15 g / L, yeast powder 5 g / L, diammonium hydrogen citrate 2 g / L, K2PO4·3H2O 2.6 g / L, MgSO4·7H2O 0.1 g / L, MnSO4 0.05 g / L, Tween 80 1 mL / L, and cysteine salt 0.5 g / L.
[0040] Example 1 A composite probiotic for improving immunity and a preparation method thereof A composite probiotic for improving immunity is composed of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024, wherein the ratio of the live bacteria count of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 is 2:2:5, and the total live bacteria count of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 is 8×10 9 cfu / mL.
[0041] The preparation method of the composite probiotics of the present invention is as follows: Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951, and Bifidobacterium breve FPHC4024 are thawed and activated respectively, and then statically cultured in an MRS medium at 37°C for 24 hours according to an inoculation amount of 2%, and the obtained bacterial culture is centrifuged at 6000 rpm for 10 minutes to obtain three single bacterial bodies respectively; the three bacterial bodies are freeze-dried to obtain freeze-dried bacterial powder, the live bacterial count ratio of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 is 2:2:5, and the total live bacterial count of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 is 8×10 9 cfu / mL, and mixed to obtain composite probiotics.
[0042] Example 2 A composite probiotic for improving immunity and its preparation method A composite probiotic for improving immunity is composed of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024, wherein the ratio of the live bacteria count of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 is 1:3:3, and the total live bacteria count of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 is 9×10 9 cfu / mL.
[0043] The preparation method of the composite probiotics of the present invention is as follows: Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951, and Bifidobacterium breve FPHC4024 are thawed and activated respectively, and then statically cultured in an MRS medium at 37°C for 24 hours according to an inoculation amount of 2%, and the obtained bacterial culture is centrifuged at 6000 rpm for 10 minutes to obtain three single bacterial bodies respectively; the three bacterial bodies are freeze-dried to obtain freeze-dried bacterial powder, the live bacterial count ratio of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 is 1:3:3, and the total live bacterial count of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 is 9×10 9 cfu / mL, and mixed to obtain composite probiotics.
[0044] Example 3 A composite probiotic for improving immunity and its preparation method A composite probiotic for improving immunity is composed of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024, wherein the ratio of the live bacteria count of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 is 3:3:6, and the total live bacteria count of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 is 6×10 9 cfu / mL.
[0045] The preparation method of the composite probiotics of the present invention is as follows: Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951, and Bifidobacterium breve FPHC4024 are thawed and activated respectively, and then statically cultured in an MRS medium at 37°C for 24 hours according to an inoculation amount of 2%, and the obtained bacterial culture is centrifuged at 6000 rpm for 10 minutes to obtain three single bacterial bodies respectively; the three bacterial bodies are freeze-dried to obtain freeze-dried bacterial powder, the live bacterial count ratio of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 is 3:3:6, and the total live bacterial count of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 is 6×10 9 cfu / mL, and mixed to obtain composite probiotics.
[0046] Example 4 A composite probiotic for improving immunity and its preparation method A composite probiotic for improving immunity is composed of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024, wherein the ratio of the live bacteria count of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 is 2:3:4, and the total live bacteria count of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 is 5×10 9 cfu / mL.
[0047] The preparation method of the composite probiotics of the present invention is as follows: Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951, and Bifidobacterium breve FPHC4024 are thawed and activated respectively, and then statically cultured in an MRS medium at 37°C for 24 hours according to an inoculation amount of 2%, and the obtained bacterial culture is centrifuged at 6000 rpm for 10 minutes to obtain three single bacterial bodies respectively; the three bacterial bodies are freeze-dried to obtain freeze-dried bacterial powder, the live bacterial count ratio of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 is 2:3:4, and the total live bacterial count of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 is 5×10 9 cfu / mL, and mixed to obtain composite probiotics.
[0048] Example 5 A functional yogurt and a preparation method thereof (1) Preparation of composite probiotic suspension Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951, and Bifidobacterium breve FPHC4024 were thawed and activated, and then cultured in MRS medium at 37°C for 24 hours at an inoculum size of 2%. The obtained bacterial culture was centrifuged at 6000 rpm for 10 minutes, and the bacteria were resuspended in PBS to obtain a composite probiotic suspension.
[0049] Among them, the ratio of live bacteria counts of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951, and Bifidobacterium breve FPHC4024 was 2:2:5, and the total live bacteria counts of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951, and Bifidobacterium breve FPHC4024 were 8×10 9 cfu / mL.
[0050] (2) Fermentation and ripening Add white sugar to fresh milk for preparation, the ratio of white sugar to fresh milk is 8.6 g:100 mL, and pasteurize at 75°C for 20 min to obtain a mixture of white sugar and fresh milk; after the mixture of white sugar and fresh milk is cooled to room temperature, add the composite probiotic suspension prepared in step (1) thereto, gently stir evenly, and then ferment at 35°C for 15 h, and place the fermented yogurt at 6°C for 35 h to obtain the functional yogurt of the present invention.
[0051] Example 6 A functional yogurt and a preparation method thereof (1) Preparation of composite probiotic suspension Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951, and Bifidobacterium breve FPHC4024 were thawed and activated, and then cultured in MRS medium at 37°C for 24 hours at an inoculum size of 2%. The obtained bacterial culture was centrifuged at 6000 rpm for 10 minutes, and the bacteria were resuspended in PBS to obtain a composite probiotic suspension.
[0052] Among them, the ratio of live bacteria counts of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951, and Bifidobacterium breve FPHC4024 was 1:3:3, and the total live bacteria counts of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951, and Bifidobacterium breve FPHC4024 were 6×10 9 cfu / mL.
[0053] (2) Fermentation and ripening Add white sugar to fresh milk for preparation, the ratio of white sugar to fresh milk is 6 g:100 mL, pasteurize at 72° C. for 20 min, and obtain a mixture of white sugar and fresh milk; after the mixture of white sugar and fresh milk is cooled to room temperature, add the composite probiotic suspension prepared in step (1) thereto, gently stir evenly, and then ferment at 33° C. for 18 h, and place the fermented yogurt at 4° C. for 30 h to obtain the functional yogurt of the present invention.
[0054] Example 7 A functional yogurt and its preparation method (1) Preparation of composite probiotic suspension Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951, and Bifidobacterium breve FPHC4024 were thawed and activated, and then cultured in MRS medium at 37°C for 24 hours at an inoculum size of 2%. The obtained bacterial culture was centrifuged at 6000 rpm for 10 minutes, and the bacteria were resuspended in PBS to obtain a composite probiotic suspension.
[0055] Among them, the ratio of live bacteria counts of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951, and Bifidobacterium breve FPHC4024 was 3:3:6, and the total live bacteria counts of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951, and Bifidobacterium breve FPHC4024 were 9×10 9 cfu / mL.
[0056] (2) Fermentation and ripening Add white sugar to fresh milk for preparation, the ratio of white sugar to fresh milk is 10 g:100 mL, pasteurize at 75° C. for 20 min, and obtain a mixture of white sugar and fresh milk; after the mixture of white sugar and fresh milk is cooled to room temperature, add the composite probiotic suspension prepared in step (1) thereto, gently stir evenly, and then ferment at 38° C. for 12 h, and place the fermented yogurt at 8° C. for 30 h to obtain the functional yogurt of the present invention.
[0057] Comparative Example 1 A composite probiotic Compared with Example 1, the difference is that the composite probiotic does not contain Bifidobacterium breve FPHC4024, but is composed of Lactobacillus helveticus LZ-R-5 and Lactobacillus reuteri FPHC2951. The details are as follows: A composite probiotic is composed of Lactobacillus helveticus LZ-R-5 and Lactobacillus reuteri FPHC2951, wherein the ratio of the live bacteria count of Lactobacillus helveticus LZ-R-5 and Lactobacillus reuteri FPHC2951 is 2:2, and the total live bacteria count of Lactobacillus helveticus LZ-R-5 and Lactobacillus reuteri FPHC2951 is 8×10 9 cfu / mL.
[0058] The preparation method of the composite probiotics is as follows: Lactobacillus helveticus LZ-R-5 and Lactobacillus reuteri FPHC2951 are thawed and activated respectively, and then statically cultured in MRS medium at 37°C for 24 hours according to an inoculation amount of 2%. The obtained bacterial culture is centrifuged at 6000rpm for 10 minutes to obtain single bacteria. The bacteria are freeze-dried to obtain freeze-dried bacterial powder. The ratio of the number of live bacteria of Lactobacillus helveticus LZ-R-5 and Lactobacillus reuteri FPHC2951 is 2:2, and the total number of live bacteria of Lactobacillus helveticus LZ-R-5 and Lactobacillus reuteri FPHC2951 is 8×10 9 cfu / mL, and mixed to obtain composite probiotics.
[0059] Comparative Example 2 A composite probiotic Compared with Example 1, the difference is that Lactobacillus reuteri LR06 is used to replace Lactobacillus reuteri FPHC2951, and the composite probiotics are composed of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri LR06 and Bifidobacterium breve FPHC4024. The details are as follows: A composite probiotic consists of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri LR06 and Bifidobacterium breve FPHC4024, wherein the ratio of the live counts of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri LR06 and Bifidobacterium breve FPHC4024 is 2:2:5, and the total live count of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri LR06 and Bifidobacterium breve FPHC4024 is 8×10 9 cfu / mL.
[0060] The preparation method of the composite probiotics is as follows: Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri LR06, and Bifidobacterium breve FPHC4024 are thawed and activated respectively, and then statically cultured in MRS medium at 37°C for 24 hours according to an inoculation amount of 2%. The obtained bacterial culture is centrifuged at 6000rpm for 10 minutes to obtain three single bacteria. The three bacteria are freeze-dried to obtain freeze-dried bacterial powder. The ratio of the number of live bacteria of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri LR06, and Bifidobacterium breve FPHC4024 is 2:2:5, and the total number of live bacteria of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri LR06, and Bifidobacterium breve FPHC4024 is 8×10 9 cfu / mL, and mixed to obtain composite probiotics.
[0061] Comparative Example 3 A composite probiotic Compared with Example 1, the difference is that the compounding ratio of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri LR06 and Bifidobacterium breve FPHC4024 is different, and the ratio of the number of live bacteria of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 is 1:4:2. The details are as follows: A composite probiotic for improving immunity is composed of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024, wherein the ratio of the live bacteria count of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 is 1:4:2, and the total live bacteria count of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 is 8×10 9 cfu / mL.
[0062] The preparation method of the composite probiotics is as follows: Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951, and Bifidobacterium breve FPHC4024 are thawed and activated respectively, and then statically cultured in MRS medium at 37°C for 24 hours according to an inoculation amount of 2%. The obtained bacterial culture is centrifuged at 6000rpm for 10 minutes to obtain three single bacteria. The three bacteria are freeze-dried to obtain freeze-dried bacterial powder. The ratio of the number of live bacteria of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951, and Bifidobacterium breve FPHC4024 is 1:4:2, and the total number of live bacteria of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951, and Bifidobacterium breve FPHC4024 is 8×10 9 cfu / mL, and mixed to obtain composite probiotics.
[0063] Comparative Example 4 A yogurt was prepared by the following method: (1) Preparation of composite probiotic suspension Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri LR06, and Bifidobacterium breve FPHC4024 were thawed and activated, and then cultured in MRS medium at 37°C for 24 hours at an inoculation rate of 2%. The obtained bacterial culture was centrifuged at 6000 rpm for 10 minutes, and the bacteria were resuspended in PBS to obtain a composite probiotic suspension.
[0064] Among them, the ratio of live bacteria counts of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri LR06, and Bifidobacterium breve FPHC4024 was 2:2:5, and the total live bacteria counts of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri LR06, and Bifidobacterium breve FPHC4024 were 8×10 9 cfu / mL.
[0065] (2) Fermentation and ripening Add white sugar to fresh milk for preparation, the ratio of white sugar to fresh milk is 8.6 g:100 mL, and pasteurize at 75°C for 20 min to obtain a mixture of white sugar and fresh milk; after the mixture of white sugar and fresh milk is cooled to room temperature, add the composite probiotic suspension prepared in step (1) thereto, gently stir evenly, and then ferment at 35°C for 15 h, and place the fermented yogurt at 6°C for 35 h to obtain the mixture.
[0066] Comparative Example 5 A yogurt was prepared by the following method: (1) Preparation of composite probiotic suspension After thawing and activating, Lactobacillus helveticus LZ-R-5 and Lactobacillus reuteri FPHC2951 were statically cultured in MRS medium at 37°C for 24 hours at an inoculation rate of 2%. The obtained bacterial culture was centrifuged at 6000 rpm for 10 minutes and then resuspended in PBS to obtain a composite probiotic suspension.
[0067] Among them, the ratio of live bacteria counts of Lactobacillus helveticus LZ-R-5 and Lactobacillus reuteri FPHC2951 was 2:2, and the total live bacteria counts of Lactobacillus helveticus LZ-R-5 and Lactobacillus reuteri FPHC2951 were 8×10 9 cfu / mL.
[0068] (2) Fermentation and ripening Add white sugar to fresh milk for preparation, the ratio of white sugar to fresh milk is 8.6 g:100 mL, and pasteurize at 75°C for 20 min to obtain a mixture of white sugar and fresh milk; after the mixture of white sugar and fresh milk is cooled to room temperature, add the composite probiotic suspension prepared in step (1) thereto, gently stir evenly, and then ferment at 35°C for 15 h, and place the fermented yogurt at 6°C for 35 h to obtain the mixture.
[0069] Comparative Example 6 A yogurt was prepared by the following method: (1) Preparation of composite probiotic suspension Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951, and Bifidobacterium breve FPHC4024 were thawed and activated, and then cultured in MRS medium at 37°C for 24 hours at an inoculum size of 0.5%. The obtained bacterial culture was centrifuged at 5000 rpm for 20 minutes, and then the bacteria were resuspended in PBS to obtain a composite probiotic suspension.
[0070] Among them, the ratio of live bacteria counts of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951, and Bifidobacterium breve FPHC4024 was 2:2:5, and the total live bacteria counts of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951, and Bifidobacterium breve FPHC4024 were 8×10 9 cfu / mL.
[0071] (2) Fermentation and ripening Add white sugar to fresh milk for preparation, the ratio of white sugar to fresh milk is 5g:100mL, pasteurize at 75°C for 20min, and obtain a mixture of white sugar and fresh milk; after the mixture of white sugar and fresh milk is cooled to room temperature, add the composite probiotic suspension prepared in step (1) thereto, gently stir evenly, and then ferment at 35°C for 22h to obtain the mixture.
[0072] Effect Example 1 Study on the effect of the composite probiotics of the present invention on the immune function of mice
[0073] 1. Experimental animals and groups 96 SPF grade Kunming mice, weighing 18-22g. The 96 mice were divided into 2 batches for experiments. The first batch of mice was subjected to an experiment for measuring the ratio of organs to body weight; the second batch of mice was subjected to an experiment for phagocytosis of chicken red blood cells by mouse peritoneal macrophages. Each batch of mice was randomly divided into 6 groups according to body weight, namely, a blank control group, Example 1 group, Example 2 group, Comparative Example 1 group, Comparative Example 2 group, and Comparative Example 3 group, with 8 mice in each group.
[0074] The Example 1 group, the Example 2 group, the Comparative Example 1 group, the Comparative Example 2 group, the Comparative Example 3 group were respectively gavaged with 50 mg / mL of the composite probiotics prepared in Example 1, Example 2, Comparative Example 1, Comparative Example 2, and Comparative Example 3, 0.2 mL / (mouse·d); the blank control group was gavaged with normal saline, 0.2 mL / (mouse·d); gavage was performed once a day, and gavage was continued for 28 days according to the experimental needs. During the test period, feed was added to the mice and drinking water was replaced in time every day. Except for regular gavage, the mice were free to eat and drink water. The sawdust for bedding was replaced regularly to keep the environment sanitary and clean. The general condition of the mice was observed every day.
[0075] 2 Test methods 2.1 Determination of organ-to-body weight ratio After each group of mice were gavaged continuously for 28 days, they were fasted 12 hours before being killed. The mice were weighed and their body weights were recorded. The mice were killed by cervical dislocation, and their spleens and thymuses were removed. The fat and connective tissue around the organs were removed, and the wet weights of the spleen and thymus were weighed with an electronic balance to calculate the organ index.
[0076] Thymus index = thymus weight (mg) / body weight (10g).
[0077] Spleen index = spleen weight (mg) / body weight (10g).
[0078] 2.2 Experiment on phagocytosis of chicken red blood cells by mouse peritoneal macrophages Each group of mice was gavaged continuously for 28 days. 30 minutes after the last gavage, 1 mL of 5% (v / v) packed volume chicken red blood cell suspension was injected into the peritoneal cavity of each mouse for immunization. The macrophage phagocytosis percentage and macrophage phagocytosis index were determined by drop plate method.
[0079] Phagocytosis percentage = (number of macrophages phagocytosing chicken red blood cells in 100 macrophages / 100 macrophages) × 100%.
[0080] Phagocytic index = total number of chicken red blood cells phagocytosed by 100 macrophages / 100 macrophages.
[0081] 3. Statistical methods SPSS22.0 software was used for data processing. The data were expressed as mean ± standard deviation (`x±s). Normal distribution test and variance homogeneity test were performed on the data of each group. One-way analysis of variance was used for inter-group comparison. P < 0.05 was considered statistically significant.
[0082] 4. Results and Discussion 4.1 Effect of the composite probiotics of the present invention on the body weight of mice After continuous intragastric administration of the composite probiotics of the present invention and physiological saline to mice for 28 days, the mice were weighed. Figure 1 .
[0083] The average body weight of the composite probiotic mice in Example 1 group, Example 2 group, Comparative Example 1 group, Comparative Example 2 group, and Comparative Example 3 group was significantly increased compared with the blank control group, with significant differences, indicating that the composite probiotics of the present invention have a promoting effect on the increase of the body weight of mice.
[0084] 4.2 Effects of the composite probiotics of the present invention on immune indicators of mice Compared with the blank control group, the spleen index and thymus index of mice in Example 1 group, Example 2 group, and Comparative Example 1-3 groups were significantly increased. Figure 2 and Figure 3 The effect of improving spleen index and thymus index in Example 1 is better than that in Comparative Examples 1-3.
[0085] Compared with the blank control group, the phagocytic rate and phagocytic index of mice in Example 1 group, Example 2 group, and Comparative Example 1-3 groups were significantly improved. Figure 4 and Figure 5 The effect of improving the phagocytic rate and phagocytic index in Example 1 is better than that in Comparative Examples 1-3.
[0086] By the determination test of organ weight ratio and the test of mouse peritoneal macrophage phagocytosis of chicken erythrocyte, it is shown that the composite probiotics of the present invention significantly improve immunity. The effect of the composite probiotics of the embodiment 1 group and the embodiment 2 group in improving immunity is significantly better than that of the comparative example 1-3 group. Under the same dose, lack of Bifidobacterium breve FPHC4024, or replacement of Lactobacillus reuteri FPHC2951 with Lactobacillus reuteri LR06, or changing the ratio of three bacteria of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024, the immunoenhancing effect of the composite probiotics prepared is significantly weakened. It is shown that the three specific strains of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 have played a significant synergistic effect in improving immunity according to a specific ratio, and have significant technical advantages.
[0087] Effect Example 2 Study on the effect of the functional yogurt of the present invention on immune function
[0088] 1. Experimental animals and groups 40 SPF Kunming mice weighing 18-22 g were randomly divided into a blank control group, Example 5 group, Comparative Example 4 group, Comparative Example 5 group, and Comparative Example 6 group according to their body weight, with 8 mice in each group.
[0089] The Example 5 group, the Comparative Example 4 group, the Comparative Example 5 group, and the Comparative Example 6 group were gavaged with 60 mg / mL of the yogurt prepared in Example 5, Comparative Example 4, Comparative Example 5, and Comparative Example 6, 0.5 mL / (mouse·d); the blank control group was gavaged with normal saline, 0.5 mL / (mouse·d); the mice were gavaged once a day, and had a normal diet and water intake for 10 consecutive days, and then fasted for 1 day. On the 2nd day after fasting, the eyeballs were removed to collect blood, and then the mice were killed by cervical dislocation.
[0090] 2. Test methods Effect of functional yogurt of the present invention on immunoglobulins (IgA, IgM, IgG) in mice The blood obtained by removing the eyeball was placed in a 4°C refrigerator overnight, and then centrifuged at 3000r / min for 15min. The supernatant was separated to obtain serum, and the contents of IgA, IgM and IgG were determined by indirect enzyme-linked immunosorbent assay.
[0091] 3. Statistical methods SPSS22.0 software was used for data processing. The data were expressed as mean ± standard deviation (`x±s). Normal distribution test and variance homogeneity test were performed on the data of each group. One-way analysis of variance was used for inter-group comparison. P < 0.05 was considered statistically significant.
[0092] 4. Results and Discussion 4.1 Effect of the functional yogurt of the present invention on the serum immunoglobulin content of mice Immunoglobulin is the main antibody that mediates humoral immunity. The level of serum antibody reflects the body's resistance to disease to a certain extent. The determination of serum immunoglobulin is a common method for checking the level of humoral immunity. Usually, the detection of IgG, IgA, and IgM can represent the overall level of serum immunoglobulin.
[0093] Depend on Figure 6-Figure 8 It can be seen that the functional yogurt of the present invention can significantly increase the IgG, IgA and IgM content in the serum of mice and improve the immune function of mice. The effect of improving immunity of the functional yogurt prepared in Example 5 of the present invention is significantly better than that of the yogurt prepared in Comparative Examples 4, 5 and 6.
[0094] The above embodiments are merely examples for clear explanation and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description, and the obvious changes or modifications derived therefrom are still within the scope of protection of the present invention.
Claims
1. A compound probiotic that improves immunity, It is characterized in that The composite probiotics are composed of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024; The Lactobacillus helveticus LZ-R-5 was deposited in the General Microbiology Center of China Microorganism Culture Collection Administration on June 24, 2021, with the deposit address at No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, and the deposit number is CGMCC NO.22776; The Lactobacillus reuteri FPHC2951 was deposited in Guangdong Microbiological Culture Collection Center on November 3, 2022, with the deposit address being 5th Floor, Building 59, No. 100, Xianlie Middle Road, Guangzhou City, Guangdong Province, China, and the deposit number is GDMCC NO.62946; The Bifidobacterium breve FPHC4024 was deposited in Guangdong Provincial Microbiological Culture Collection Center on November 3, 2022, with the deposit address being 5th Floor, Building 59, No. 100, Xianlie Middle Road, Guangzhou City, Guangdong Province, China, and the deposit number is GDMCC NO.62945; The ratio of the live bacteria counts of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 is 1-3:1-3:3-6.
2. The composite probiotic according to claim 1, It is characterized in that The ratio of the live bacteria counts of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 is 2:2:3-6.
3. The composite probiotic according to claim 2, It is characterized in that The ratio of the live bacteria counts of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 is 2:2:
5.
4. The composite probiotic according to claim 1, It is characterized in that The total number of viable bacteria in the composite probiotics is 5-9×10 9 cfu / mL.
5. The composite probiotic according to claim 1, It is characterized in that The preparation method of the composite probiotics is as follows: Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 are thawed and activated respectively, and then statically cultured in an MRS medium at 37°C for 24 hours according to an inoculation amount of 2%, and the obtained bacterial culture is centrifuged at 6000rpm for 10 minutes to obtain three single bacterial bodies respectively; the three bacterial bodies are freeze-dried to obtain freeze-dried bacterial powder, and the ratio of the live bacterial counts of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 is 1-3:1-3:3-6, and the total live bacterial counts of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 are 8×10 9 cfu / mL, and mixed to obtain composite probiotics.
6. Use of the composite probiotic according to claim 1 in preparing a health product for improving immunity.
7. A functional yogurt, It is characterized in that The functional yogurt is obtained by inoculating the composite probiotics described in claim 1 into sweetened fresh milk and fermenting and ripening it; the live bacterial count ratio of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 is 1-3:1-3:3-6; the total live bacterial count of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951 and Bifidobacterium breve FPHC4024 is 6-8×10 9 cfu / mL; the fermentation temperature is 33-38°C, and the fermentation time is 12-18h; the ripening temperature is 4-8°C, and the ripening time is 30-40h; the sugar is white sugar, and the ratio of the white sugar to fresh milk is 6-10g:100mL.
8. The functional yogurt according to claim 7, It is characterized in that The ratio of the live bacteria counts of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951, and Bifidobacterium breve FPHC4024 is 2:2:5; the total live bacteria counts of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951, and Bifidobacterium breve FPHC4024 are 8×10 9 cfu / mL; the fermentation temperature is 35°C, and the fermentation time is 15h; the ripening temperature is 6°C, and the ripening time is 35h; the ratio of the white sugar to the fresh milk is 8.6g:100mL.
9. A functional yogurt powder, obtained by spray-drying the functional yogurt according to claim 7 or 8.
Citation Information
Patent Citations
Lactobacillus helveticus LZ-R-5 capable of producing exopolysaccharides and having immunoregulation capability and application of lactobacillus helveticus LZ-R-5
CN114196561A
Bifidobacterium breve FPHC4024 for preventing and treating infantile diarrhea and application thereof
CN116970530A
Probiotic strain, application thereof and composition for preventing and treating infantile diarrhea
CN117018043A
Bifidobacterium breve and application thereof
CN117305171A
Probiotic composition for reducing blood fat and application thereof
CN118516257A
Cited By
Probiotic compound capable of reducing uric acid and application of probiotic compound
CN119709520A
A uric acid-lowering probiotic complex and its application
CN119709520B
